Search

everythinglearnresearchcommunity

for

Search:↓

A 28-year-old man regrew hair using 1mg finasteride, 2.5mg oral minoxidil, a multivitamin, and a derma roller over 1 year and 9 months. Initial side effects resolved, and he maintains his hair with continued treatment.

The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.

GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.

A user shared a 17-month update on their hair loss treatment, which included a hair transplant of 2300 grafts, using a topical solution of minoxidil and finasteride, a laser cap, and ketoconazole shampoo. They are considering another transplant and seeking honest feedback on their progress, while others share their own experiences and advice on hair loss treatments.

A 28-year-old male shares his hair regrowth progress using finasteride, topical and oral minoxidil, hair peptide serum, ketoconazole shampoo, dermastamping, multivitamins, and a high-protein diet. He reports noticeable hair growth and minor side effects, emphasizing patience as key to success.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

A 26-year-old shared their 2-month progress using finasteride, minoxidil, microneedling (1mm weekly), and vitamin D3 for hair loss. They are pleased with the results.

A 25-year-old male experienced hair regrowth after switching from topical minoxidil to a combination of topical minoxidil and oral finasteride, along with microneedling and multivitamins. He reported no significant side effects from finasteride, except mild discomfort, and emphasized the effectiveness of oral finasteride over topical solutions.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

The user asked for opinions on a hair loss treatment involving PRP and Exosomes. They recently tried this treatment.

The conversation discusses the use of Verteporfin in treating hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The user is frustrated with Koshinemall's disorganized service and delayed shipping of KX-826. They are seeking feedback on whether others have received their KX-826 orders.

The user experienced significant hair regrowth using topical Minoxidil and Finasteride but had to stop due to high liver enzyme levels. They plan to pause treatment for a month to see if their liver values return to normal.

The conversation discusses the progress and potential of hair cloning by Stemson Therapeutics, questioning if it will be realized in the next 5-10 years or if it's just false hope. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

Exploring potential treatments for hair loss, with the focus being on comparing RU58841 and Pyrilutamide. Finasteride, Dutasteride, oral Minoxidil, microneedling, topical Minoxidil, Biotin, Zinc, Vitamin D and Nizoral are also discussed as part of a treatment stack.

The user experienced hair regrowth and improved hair density using oral finasteride and topical minoxidil, with microneedling as an additional treatment. They are considering a hair transplant for low-density areas but are uncertain due to existing follicles.

A 19-year-old with rapid hair loss since 16 is considering a hair transplant but refuses to take finasteride or any 5α-Reductase inhibitors. They are currently using minoxidil, tretinoin, and microneedling with a Derminator 2, and only want hair until age 27.

The user, a 27-year-old male, has been treating early hair loss with topical finasteride and minoxidil, then switched to oral finasteride and dutasteride, but has seen no improvement and plans to add oral minoxidil. Despite treatment, hair loss has progressed from Norwood 1-1.5 to Norwood 3, with noticeable thinning, especially on the left side.

The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

A 25-year-old shared progress after a year using oral finasteride, topical minoxidil, and microneedling, noting significant hair improvement despite periodic shedding. The user experienced body hair loss as a side effect but reported no other issues and plans to continue the treatment.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

Significant hair regrowth was achieved using EssenGen 6-Plus with 6% minoxidil and 0.05% finasteride, along with Nizoral shampoo, over 12 weeks. No side effects were experienced, highlighting the benefits of a low dose.

Hair regrowth using 0.9% KX-826 every morning and 5% Minoxidil every night. Results are not expected in 45 days; more time is needed.

Akinfenrawr experienced negative side effects from oral finasteride and RU58841, and is seeking alternative hair loss treatments. They discuss various options, including raloxifene, oral dutasteride, liposomal finasteride, Breezula, Pyrilutamide, SM04554, and sulforaphane, but have concerns about efficacy, availability, and cost.

Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.

A 27-year-old male is experiencing a recurring pattern of hair loss after 5 months of using oral minoxidil and finasteride, despite initial success. He is considering using topical androgen receptor blockers like RU58841, pyrilutamide, or clascoterone to address potential androgen receptor hypersensitivity.